Barbara Eichhorst, MD from University of Cologne, Cologne, Germany outlines current clinical research in chronic lymphocytic leukemia (CLL). Dr Eichhorst discusses the recruitment of patients in the CLL14 trial which is testing efficacy and safety of obinutuzumab plus venetoclax versus obinutuzumab plus chlorambucil (NCT02242942). She then continues to discuss the upcoming results from the Phase II CLL2-GiVe trial which involved an induction treatment of bendamustine followed by maintenance treatment of ibrutinib or venetoclax in combination with obinutuzumab (NCT02758665). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Updates from the CLL14 and CLL2-GiVe trials on CLL
